Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises

被引:5
|
作者
O'Connell, Aoife K. [1 ]
Douam, Florian [1 ]
机构
[1] Boston Univ, Sch Med, Dept Microbiol, Natl Emerging Infect Dis Labs, Boston, MA 02118 USA
关键词
animal model; bacterial vaccine; humanized mice; immune response to vaccine; immunogenicity; live-attenuated vaccine; vaccine; viral vaccine; YELLOW-FEVER VIRUS; HUMAN IMMUNE-SYSTEM; T-CELL RESPONSES; SCID IL2R-GAMMA(NULL) MICE; HUMAN HEMATOPOIETIC NICHE; AMINO-ACID SUBSTITUTIONS; BACILLUS-CALMETTE-GUERIN; MYCOBACTERIUM-BOVIS BCG; MEASLES-VIRUS; MOUSE MODEL;
D O I
10.3390/vaccines8010036
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Live-attenuated vaccines (LAV) represent one of the most important medical innovations in human history. In the past three centuries, LAV have saved hundreds of millions of lives, and will continue to do so for many decades to come. Interestingly, the most successful LAVs, such as the smallpox vaccine, the measles vaccine, and the yellow fever vaccine, have been isolated and/or developed in a purely empirical manner without any understanding of the immunological mechanisms they trigger. Today, the mechanisms governing potent LAV immunogenicity and long-term induced protective immunity continue to be elusive, and therefore hamper the rational design of innovative vaccine strategies. A serious roadblock to understanding LAV-induced immunity has been the lack of suitable and cost-effective animal models that can accurately mimic human immune responses. In the last two decades, human-immune system mice (HIS mice), i.e., mice engrafted with components of the human immune system, have been instrumental in investigating the life-cycle and immune responses to multiple human-tropic pathogens. However, their use in LAV research has remained limited. Here, we discuss the strong potential of LAVs as tools to enhance our understanding of human immunity and review the past, current and future contributions of HIS mice to this endeavor.
引用
收藏
页数:42
相关论文
共 50 条
  • [31] Quadrivalent Ann Arbor strain live-attenuated influenza vaccine
    Toback, Seth L.
    Levin, Myron J.
    Block, Stan L.
    Belshe, Robert B.
    Ambrose, Christopher S.
    Falloon, Judith
    EXPERT REVIEW OF VACCINES, 2012, 11 (11) : 1293 - 1303
  • [32] Development of a novel equine influenza virus live-attenuated vaccine
    Rodriguez, Laura
    Reedy, Stephanie
    Nogales, Aitor
    Murcia, Pablo R.
    Chambers, Thomas M.
    Martinez-Sobrido, Luis
    VIROLOGY, 2018, 516 : 76 - 85
  • [33] Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
    Yeh, Ming Te
    Bujaki, Erika
    Dolan, Patrick T.
    Smith, Matthew
    Wahid, Rahnuma
    Konz, John
    Weiner, Amy J.
    Bandyopadhyay, Ananda S.
    Van Damme, Pierre
    De Coster, Ilse
    Revets, Hilde
    Macadam, Andrew
    Andino, Raul
    CELL HOST & MICROBE, 2020, 27 (05) : 736 - +
  • [34] Characterization of a live-attenuated HCMV-based vaccine platform
    Patrizia Caposio
    Sjoerd van den Worm
    Lindsey Crawford
    Wilma Perez
    Craig Kreklywich
    Roxanne M. Gilbride
    Colette M. Hughes
    Abigail B. Ventura
    Robert Ratts
    Emily E. Marshall
    Daniel Malouli
    Michael K. Axthelm
    Daniel Streblow
    Jay A. Nelson
    Louis J. Picker
    Scott G. Hansen
    Klaus Früh
    Scientific Reports, 9
  • [35] A Bivalent Live-Attenuated Vaccine for the Prevention of Equine Influenza Virus
    Blanco-Lobo, Pilar
    Rodriguez, Laura
    Reedy, Stephanie
    Oladunni, Fatai S.
    Nogales, Aitor
    Murcia, Pablo R.
    Chambers, Thomas M.
    Martinez-Sobrido, Luis
    VIRUSES-BASEL, 2019, 11 (10):
  • [36] Engineering a new vaccine platform for heterologous antigen delivery in live-attenuated Mycobacterium tuberculosis
    Broset, Esther
    Calvet Seral, Juan
    Arnal, Carmen
    Uranga, Santiago
    Kanno, Alex, I
    Leite, Luciana C. C.
    Martin, Carlos
    Gonzalo-Asensio, Jesus
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2021, 19 : 4273 - 4283
  • [37] Reverse genetic platform for inactivated and live-attenuated influenza vaccine
    Eun-Ju Jung
    Kwang-Hee Lee
    Baik Lin Seong
    Experimental & Molecular Medicine, 2010, 42 : 116 - 121
  • [38] Reverse genetic platform for inactivated and live-attenuated influenza vaccine
    Jung, Eun-Ju
    Lee, Kwang-Hee
    Seong, Baik Lin
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2010, 42 (02): : 116 - 121
  • [39] Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design
    VanBuskirk, Kelley M.
    O'Neill, Matthew T.
    De la Vega, Patricia
    Maier, Alexander G.
    Krzych, Urszula
    Williams, Jack
    Dowler, Megan G.
    Sacci, John B., Jr.
    Kangwanrangsan, Niwat
    Tsuboi, Takafumi
    Kneteman, Norman M.
    Heppner, Donald G., Jr.
    Murdock, Brant A.
    Mikolajczak, Sebastian A.
    Aly, Ahmed S. I.
    Cowman, Alan F.
    Kappe, Stefan H. I.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (31) : 13004 - 13009
  • [40] Characterization of a live-attenuated HCMV-based vaccine platform
    Caposio, Patrizia
    van den Worm, Sjoerd
    Crawford, Lindsey
    Perez, Wilma
    Kreklywich, Craig
    Gilbride, Roxanne M.
    Hughes, Colette M.
    Ventura, Abigail B.
    Ratts, Robert
    Marshall, Emily E.
    Malouli, Daniel
    Axthelm, Michael K.
    Streblow, Daniel
    Nelson, Jay A.
    Picker, Louis J.
    Hansen, Scott G.
    Fruh, Klaus
    SCIENTIFIC REPORTS, 2019, 9 (1)